Nasdaq reports that Pfizer has completed its acquisition of Illinois-based medical device company Hospira. Based on recent device recalls, the Hospira acquisition may result in additional lawsuits for Pfizer, which is already defending a number of its own cases involving Lipitor and Zoloft.
The past six months have seen a slew of recalls and warning letters from the U.S. Food and Drug Administration (FDA) concerning Hospira ...
continue reading...
The U.S. Food and Drug Administration (FDA) recently issued a safety alert warning health care facilities and providers to suspend or avoid use of Hospira’s Symbiq Infusion System. The announcement came after the FDA, the U.S. Department of Homeland Security, and the medical device manufacturer Hospira became aware of cybersecurity vulnerabilities associated with the infusion pumps.
The Hospira Symbiq Infusion System is “a computerized pump designed ...
continue reading...
The pharmaceutical company and medical device manufacturer Hospira, Inc., has issued a Class I recall of its Plum A+ and A+3 infusion pumps, according to the FDA website. The pumps have an alarm that is supposed to trigger when therapy is interrupted. However, some of the pumps’ alarms fail to sound in situations that should trigger them.
Class I recalls are the most serious class of recalls, and are ...
continue reading...
